Search

Displaying results 2811 - 2820 of 10000 in total
  1. Drug

    Apraclonidine

    go.drugbank.com/drugs/DB00964
    ApprovedInvestigational

    Apraclonidine, also known as iopidine, is a sympathomimetic used in glaucoma therapy. It is an alpha2-adrenergic agonist.

  2. Drug

    Bezlotoxumab

    go.drugbank.com/drugs/DB13140
    Approved

    [L46976] On November 22, 2016, the Committee for Medicinal Products for Human Use of the European Medicines Agency recommended the granting of a marketing authorization. … [L46976] First approved by the FDA on October 21, 2016,[A260106] bezlotoxumab is used to reduce the recurrence of _C. difficile_ infection.

  3. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada. … The development of ranibizumab first began after [bevacizumab], another anti-VEGF anticancer drug, was discovered to inhibit neovascularization and used in the off-label treatment of neovascular age-related

    Products: LUCENTIS® 10 MG /ML SOLUCION INYECTABLE, LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
  4. Drug

    Deutivacaftor

    go.drugbank.com/drugs/DB15141
    ApprovedInvestigational

    It is used alongside CFTR correctors to increase the quantity and function of CFTR at the cell surface in patients with cystic fibrosis. … [L52275,A179677] Deutivacaftor was first approved by the US FDA in December 2024 in combination with two CFTR correctors - [tezacaftor] and [vanzacaftor] - for the treatment of patients with responsive

  5. Drug

    Strontium chloride Sr-89

    go.drugbank.com/drugs/DB09498
    Approved

    Strontium chloride is mainly used in cases of metastatic castrate-resistant prostate cancer.[A31264] Bone metastases is a common and severe complication presented in advanced stages of the disease. … There has been some cases of apparent tumor regression which has given it a potential tumoricidal effect.[A31263]

  6. Drug

    Fluciclovine (18F)

    go.drugbank.com/drugs/DB13146
    ApprovedInvestigational

    Fluciclovine is a [18F]-tagged synthetic analog of the amino acid L-leucine. It presents excellent diagnostic properties to be used in positron emission tomography (PET) imaging. … [A31384] The structure of fluciclovine allows it to be uptaken by the tumoral cells by its amino acid transporter without incorporating in the metabolism within the body.

  7. Drug

    Nitisinone

    go.drugbank.com/drugs/DB00348
    Approved

    Nitisinone is a synthetic reversible inhibitor of 4-hydroxyphenylpyruvate dioxygenase. It is used in the treatment of hereditary tyrosinemia type 1 and Alkaptonuria.

    Products: NITISOR® 2 MG, NITISINONA 2 MG
  8. Drug

    Cetyl alcohol

    go.drugbank.com/drugs/DB09494
    Approved

    of total alcohols and not less than 94 percent of straight chain alcohols [L1824]. … Cetyl alcohol is reported to be a mild skin or eye irritant.

    Synonyms: hexadecan-1-ol
  9. Drug

    Bretylium

    go.drugbank.com/drugs/DB01158
    Approved

    The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. … Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular

  10. Drug

    Pegzilarginase

    go.drugbank.com/drugs/DB14780
    Approved

    toxic metabolites that drive the progressive neurological phenotype of this rare urea cycle disorder. … FDA in February 2026 for the treatment of hyperargininemia in adult and pediatric patients aged 2 years and older with ARG1-D, to be used in conjunction with dietary protein restriction.